BioSpace News Archive

Cue Biopharma, Inc. announced today that it has entered into securities purchase agreements with certain accredited investors for a $30 million private investment in public equity (PIPE) financing.

Yumanity Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments.

VolitionRx Limited has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.

Tivic Health ® Systems, Inc. today announced its financial results for the quarter ended September 30, 2022.

Clarius Mobile Health, a leading provider of high-definition wireless ultrasound systems, is pleased to announce at the MEDICA International Trade Fair that it closed a record high fiscal year in 2022, growing sales at 44% over the same period last year since the global launch of Clarius HD3.

Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), today announced publication of a scientific article on the anti-cancer activity of the Company’s novel dual PARP-HDAC inhibitor in models of Ewing sarcoma.

Investigators at Hospital for Special Surgery have discovered that at the time of total knee replacement, women have significantly increased levels of immune cells called mast cells in synovial tissue surrounding the knee joint than men.

Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years.

TMD LAB and the National Institute of Standards and Technology under the U.S. Department of Commerce are starting joint research on the properties of SMP materials.

CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2022.